Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microarray-based understanding of normal and malignant plasma cells.

John De Vos1, Dirk Hose, Thierry Rème

  • 1IRB, CHU Montpellier, Montpellier, France.

Immunological Reviews
|April 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.

European journal of haematology·2026
Same author

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

European journal of haematology·2025
Same author

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.

Journal of hematology & oncology·2025
Same author

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.

Journal of hematology & oncology·2024
Same author

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.

JCO precision oncology·2024

Plasma cells are essential for antibody production. Microarray technology has advanced our understanding of plasma cell biology and their role in premalignant and malignant conditions.

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • Plasma cells (PCs) are differentiated B lymphocytes responsible for immunoglobulin synthesis.
  • PC development involves a specific genetic program, including transcription factors like PRDM1 and BHLHB3.
  • This process is linked to cell-surface molecules (e.g., CD138/syndecan-1) and the unfolded protein response.

Purpose of the Study:

  • To review the contribution of microarray technology to understanding plasma cell biology.
  • To explore the transformation of plasma cells into premalignant and malignant states.

Main Methods:

  • Review of studies utilizing microarray technology.
  • Analysis of gene expression patterns in plasma cells.

Main Results:

Related Experiment Videos

  • Microarray technology has provided insights into the complex genetic programs of plasma cells.
  • Understanding these programs is crucial for identifying factors involved in PC transformation.

Conclusions:

  • Microarray technology is a valuable tool for studying rare cell populations like plasma cells.
  • Further research into plasma cell genetics can elucidate mechanisms of premalignant and malignant transformation.